Cyclopharm Ltd (ASX: CYC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Cyclopharm Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $126.99 million
P/E Ratio N/A
Dividend Yield 0.76%
Shares Outstanding 93.37 million
Earnings per share -0.056
Dividend per share 0.01
Year To Date Return -19.82%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Cyclopharm Ltd (ASX: CYC)
Latest News

four excited doctors with their hands in the air
Share Gainers

Cyclopharm (ASX:CYC) share price jumps on trading update

Today's gains will be welcome news for shareholders after major Monday's selloff.

Read more »

falling healthcare asx share price Mesoblast capital raising
Healthcare Shares

Why the Cyclopharm (ASX:CYC) share price is crashing 42% lower

Some disappointing news from the FDA is sending investors running for the hills.

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Why is the Cyclopharm (ASX:CYC) share price down today?

The Cyclopharm Limited (ASX: CYC) share price dropped today after the company released its 2021 AGM Presentation.

Read more »

Share Market News

Why the Cyclopharm (ASX:CYC) share price popped 6% today

The Cyclopharm share price went soaring today as the company announced a market update. We take a closer look.

Read more »

Young girl wearing a suit and tie with rocket wings looks to the sky representing the highest traded stocks today
Share Market News

Why the Cyclopharma (ASX:CYC) share price surged to record high today

The Cyclopharm Limited (ASX: CYC) share price continues to bask in the glory of its clinical trial announcement released earlier…

Read more »

Dollar signs arrows pointing higher
Speculative

Cyclopharm share price rockets 22% higher on FDA application approval

The Cyclopharm Limited (ASX: CYC) share price rocketed out of the gates this morning after the company revealed it is one…

Read more »

⏸️ Investing

3 speculative micro-cap shares that could make you a fortune

Here are three sub $100 million companies with huge growth potential.

Read more »

invest
⏸️ Investing

3 cheap diversified micro-cap stocks for your portfolio

Could these three companies deliver impressive gains for your portfolio?

Read more »

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
04 Apr 2022 $0.0050 0.00% Final 12 Apr 2022
03 Sep 2021 $0.0050 0.00% Interim 13 Sep 2021
01 Apr 2021 $0.0050 0.00% Final 13 Apr 2021
04 Sep 2020 $0.0050 0.00% Interim 14 Sep 2020
30 Mar 2020 $0.0050 0.00% Final 07 Apr 2020
06 Sep 2019 $0.0050 0.00% Interim 16 Sep 2019
05 Apr 2019 $0.0050 0.00% Final 15 Apr 2019
07 Sep 2018 $0.0050 0.00% Interim 17 Sep 2018
06 Apr 2018 $0.0050 0.00% Final 16 Apr 2018
01 Sep 2017 $0.0050 0.00% Interim 11 Sep 2017
31 Mar 2017 $0.0050 0.00% Final 10 Apr 2017
02 Sep 2016 $0.0050 46.00% Interim 12 Sep 2016
11 Apr 2016 $0.0050 100.00% Interim 19 Apr 2016
05 Oct 2015 $0.0050 100.00% 14 Oct 2015

CYC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Cyclopharm Ltd

Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

CYC Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
18 May 2022 $1.36 $0.05 3.82% 13,306 $1.33 $1.37 $1.30
17 May 2022 $1.31 $0.00 0.00% 1,500 $1.31 $1.31 $1.31
16 May 2022 $1.31 $0.01 0.77% 7,874 $1.36 $1.37 $1.30
13 May 2022 $1.30 $-0.06 -4.41% 44,600 $1.33 $1.33 $1.30
12 May 2022 $1.36 $-0.01 -0.73% 3,000 $1.37 $1.37 $1.36
11 May 2022 $1.38 $-0.01 -0.72% 1,491,064 $1.38 $1.38 $1.38
10 May 2022 $1.39 $0.00 0.00% 15,705 $1.37 $1.39 $1.37
09 May 2022 $1.39 $0.01 0.73% 17,291 $1.39 $1.39 $1.38
06 May 2022 $1.38 $-0.11 -7.41% 97,968 $1.42 $1.42 $1.35
05 May 2022 $1.49 $0.00 0.00% 3,853 $1.49 $1.49 $1.49
04 May 2022 $1.49 $0.01 0.68% 32,785 $1.48 $1.49 $1.42
03 May 2022 $1.48 $-0.03 -1.99% 5,538 $1.49 $1.49 $1.48
02 May 2022 $1.51 $0.01 0.67% 10,609 $1.50 $1.51 $1.45
29 Apr 2022 $1.50 $-0.01 -0.66% 8,800 $1.51 $1.51 $1.50
28 Apr 2022 $1.51 $0.01 0.67% 34,438 $1.51 $1.52 $1.51
27 Apr 2022 $1.50 $-0.01 -0.66% 10,001 $1.50 $1.50 $1.47
26 Apr 2022 $1.51 $-0.01 -0.66% 27,882 $1.53 $1.53 $1.50
22 Apr 2022 $1.53 $0.02 1.33% 35,956 $1.53 $1.53 $1.45
21 Apr 2022 $1.50 $-0.05 -3.23% 15,135 $1.55 $1.55 $1.50
20 Apr 2022 $1.55 $0.05 3.33% 22,319 $1.52 $1.56 $1.52

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
09 Mar 2022 David Heaney Buy 10 $14,855
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr David James Heaney Non-Executive DirectorNon-Executive Chairman Nov 2006
Mr Heaney has more than 40 years experience in all aspects of wholesale banking and finance, gained in senior management roles with National Australia Bank Limited and subsidiary companies in both Australia and the US. He served as a non-executive director of Colorpak Limited from February 2004 until May 2016 and has also previously been a non-executive director of other listed and non-listed companies. He is Chair of the Risk committee.
Ms Dianne Margaret Angus Non-Executive Director Aug 2021
Ms Angus has experience working as an executive and a Director in the Biotechnology industry including with Prana Biotechnology Limited (now Alterity Therapeutics) and Florigene Limited. Dianne also has experience in corporate strategy, innovative product development, governance and compliance in our sector. She is also a Non-Executive Director of ASX Listed Companies Imagion Biosystems Limited and Neuren Pharmaceuticals Limited.
Mr James S McBrayer Chief Executive OfficerManaging DirectorCompany Secretary Jun 2008
Mr McBrayer has more than 30 years experience in nuclear medicine. He held the role of Managing Director at Lipa Pharmaceuticals, Australia's contract manufacturer of over the counter products and senior management positions with Brambles Cleanaway business and Syncor, the world's radioactive diagnostic and therapeutic pharmaceutical provider.
Mathew Farag Chief Operating Officer
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Anglo Australian Christian and Charitable Fund 13,211,332 14.15%
Barings Acceptance Limited 11,444,962 12.26%
Hsbc Custody Nominees (Australia) Limited A/C 2 9,708,240 10.40%
National Nominees Limited 9,533,466 10.21%
Chemical Overseas Limited 8,005,769 8.57%
CVC Limited 6,644,758 7.12%
Citicorp Nominees Pty Limited 3,226,788 3.46%
CS Third Nominees Pty Limited <HSBC Cust Nom AU Ltd 13 AC> 1,982,189 2.12%
McBrayer Reid Investments Pty Ltd LTIP 6 <McBrayer Clan Trust Ac> 1,721,554 1.84%
Chemical Overseas Limited (i) 1,182,239 1.27%
Phillips River Pty Ltd <GAT AC> 1,038,914 1.11%
Lloyds & Casanove Investment Partners Ltd 987,503 1.06%
CS Fourth Nominees Pty <HSBC Cust Nom AU Ltd 11 AC> 972,281 1.04%
Mr James McBrayer 861,728 0.92%
Mr James McBrayer (i) 861,728 0.92%
South Seas Holdings Pty Limited 686,538 0.74%
City & Westminster Limited 556,327 0.60%
Mathew Farag <LTIP Account Holding 4> 500,000 0.54%
McBrayer Reid Investments Pty Limited <McBrayer Clan LTIP 8 Ac> 500,000 0.54%
Malackey Holdings Pty Ltd 431,758 0.46%

Profile

since

Note